Medicare Covers Next Generation Sequencing Tests for Advanced Cancer
The Centers for Medicare & Medicaid Services Friday issued a national decision to cover diagnostic laboratory tests using next generation sequencing for certain Medicare patients with advanced cancer. “These tests can help doctors consult with patients about more targeted care or enrollment in a clinical trial,” said CMS Chief Medical Officer Kate Goodrich, M.D. “The expanded coverage in this final [national coverage determination] now includes additional tests for relapsed, refractory and earlier stage III cancers to aid in the treatment of these cancer patients.”
Related News Articles
Perspective
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…
Headline
The Centers for Medicare & Medicaid Services Jan. 26 released proposed changes to Medicare Advantage plan capitation rates and Part D payment policies for…
Headline
The AHA Jan. 26 expressed support and provided its perspective on certain provisions within the Centers for Medicare & Medicaid Services’ proposed…
Headline
The AHA Jan. 20 made recommendations to Congress on modernizing the Medicare Access and CHIP Reauthorization Act. Among the proposals, the AHA recommended…
Headline
The comment period for the Centers for Medicare & Medicaid Services' proposed rule for policies governing the Medicare Advantage and Part D programs for…